SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Regulation FD Disclosure
ITEM7.01.REGULATION FD DISCLOSURE
A copy of a slide presentation that Second Sight Medical
Products, Inc. (Second Sight ) intends to use during
presentations made before groups and in hosting one-on-one
meetings with individuals at the 18th Annual B. Riley
Institutional Investor Conference in Santa Monica, California on
May 25, 2017 (the Presentation Materials), is attached to this
Current Report on Form 8-K as Exhibit 99.1 and is incorporated by
reference herein.The Presentation Materials speak as of the date
of this Current Report on Form 8-K. WhileSecond Sightmay elect to
update the Presentation Materials in the future or reflect events
and circumstances occurring or existing after the date of this
Current Report on Form 8-K,Second Sight specifically disclaims
any obligation to do so.Additionally, Second Sight has posted the
Presentation Materials on the Investor Relations section of
Second Sight’s website: http://investors.secondsight.com. The
information contained in this Item 7.01 and Exhibit 99.1 hereto
shall not be deemed filed for purposes of Section 18 of the
Securities Exchange Act of 1934, as amended (the Exchange Act),
or incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as shall be
expressly set forth by reference in such a filing.
ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS
| Exhibit No. | Description |
| 99.1 |
Second Sight Medical Products, Inc. Investor Presentation dated May 2017 |
About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)
Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina. SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Recent Trading Information
SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) closed its last trading session up +0.04 at 1.22 with 420,184 shares trading hands.